Crinetics Pharmaceuticals, Inc. (CRNX) — Analyst outlook / Analyst consensus target is. Based on 18 analyst ratings, the consensus is bullish — 18 Buy.
The consensus price target is $86.60 (low: $67.00, high: $105.00), representing an upside of 117.9% from the current price $39.75.
Analysts estimate Earnings Per Share (EPS) of $-3.69 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-3.69 vs est $-3.69 (beat +0%). 2025: actual $-4.95 vs est $-5.03 (beat +1.6%). Analyst accuracy: 99%.
CRNX Stock — 12-Month Price Forecast
$86.60
▲ +117.86% Upside
Average Price Target
Based on 18 Wall Street analysts offering 12-month price targets for Crinetics Pharmaceuticals, Inc., the average price target is $86.60, with a high forecast of $105.00, and a low forecast of $67.00.
The average price target represents a +117.86% change from the last price of $39.75.
Highest Price Target
$105.00
Average Price Target
$86.60
Lowest Price Target
$67.00
CRNX Analyst Ratings
Buy
Based on 18 analysts giving stock ratings to Crinetics Pharmaceuticals, Inc. in the past 3 months
EPS Estimates — CRNX
99%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$3.69
vs Est –$3.69
▲ 0.0% off
2025
Actual –$4.95
vs Est –$5.03
▲ 1.6% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — CRNX
63%
Analyst Accuracy
Fair
2 years compared
Actual vs Estimate
2024
Actual $0.001B
vs Est $0.002B
▼ 56.6% off
2025
Actual $0.008B
vs Est $0.006B
▲ 17.8% off
Revenue Trend
Strong revenue growth over the period shown. Analysts forecast revenue contraction ahead.
